Literature DB >> 9857954

Anticonvulsant effects of melatonin in amygdala-kindled rats.

M Mevissen1, U Ebert.   

Abstract

Different doses of melatonin (50-100 mg/kg i.p.) were tested for their ability to suppress complex partial seizures in the amygdala kindling model of the rat. Thirty minutes after injection of 75 or 100 mg/kg melatonin, the current threshold necessary to elicit epileptic afterdischarges (ADT) was significantly increased by about 200 or 250%, respectively. These doses were also sufficient to suppress generalised seizures at threshold current. All doses of melatonin decreased body temperature by more than 0.5 degrees C, but caused no pronounced ataxia. Seizure susceptibility in terms of ADT changed with the time of the day but seems not to depend on the circadian variation of endogenous melatonin, since the highest ADT was found in the morning when endogenous melatonin levels are low.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9857954     DOI: 10.1016/s0304-3940(98)00790-3

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

Review 1.  The therapeutic potential of melatonin: a review of the science.

Authors:  Samir Malhotra; Girish Sawhney; Promila Pandhi
Journal:  MedGenMed       Date:  2004-04-13

2.  Sudden death in epileptic rats exposed to nocturnal magnetic fields that simulate the shape and the intensity of sudden changes in geomagnetic activity: an experiment in response to Schnabel, Beblo and May.

Authors:  M A Persinger; B E McKay; C A O'Donovan; S A Koren
Journal:  Int J Biometeorol       Date:  2004-11-16       Impact factor: 3.787

3.  Patients with intractable epilepsy have low melatonin, which increases following seizures.

Authors:  C W Bazil; D Short; D Crispin; W Zheng
Journal:  Neurology       Date:  2000-12-12       Impact factor: 9.910

4.  A randomized, double-blind, placebo controlled trial of melatonin add-on therapy in epileptic children on valproate monotherapy: effect on glutathione peroxidase and glutathione reductase enzymes.

Authors:  Madhur Gupta; Yogendra Kumar Gupta; Sarita Agarwal; Satinder Aneja; Kamlesh Kohli
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

5.  Synthesis of valproic acid amides of a melatonin derivative, a piracetam and amantadine for biological tests.

Authors:  N Chatterjie; G Alexander; H Wang
Journal:  Neurochem Res       Date:  2001-10       Impact factor: 3.996

6.  Melatonin supplementation for the treatment of infantile spasms: protocol for a randomised placebo-controlled triple-blind trial.

Authors:  Yulin Sun; Weiwei Feng; Jian Chen; Miao Liu; Xiuyu Shi; Jing Wang; Liping Zou; Tao Xu; Guang Yang
Journal:  BMJ Open       Date:  2022-07-04       Impact factor: 3.006

Review 7.  Progress in neuroprotective strategies for preventing epilepsy.

Authors:  Munjal M Acharya; Bharathi Hattiangady; Ashok K Shetty
Journal:  Prog Neurobiol       Date:  2007-12-08       Impact factor: 11.685

8.  Evaluation of the role of chronic daily melatonin administration and pinealectomy on penicillin-induced focal epileptiform activity and spectral analysis of ECoG in rats: an in vivo electrophysiological study.

Authors:  Mehmet Yildirim; Selcen Aydin-Abidin; Ismail Abidin; Metehan Akca; Sinan Canpolat; Ali Cansu
Journal:  Neurochem Res       Date:  2013-05-14       Impact factor: 3.996

Review 9.  Melatonin as add-on treatment for epilepsy.

Authors:  Francesco Brigo; Stanley C Igwe; Alessandra Del Felice
Journal:  Cochrane Database Syst Rev       Date:  2016-08-11

10.  Antioxidants as a preventive treatment for epileptic process: a review of the current status.

Authors:  Boštjan Martinc; Iztok Grabnar; Tomaž Vovk
Journal:  Curr Neuropharmacol       Date:  2014-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.